

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

15 Aug 2026

### Comparing de novo versus delayed tacrolimus administration on allograft function in kidney transplant recipients: a randomized, open-label, clinical trial

#### Protocol summary

##### Summary

The purpose of the study: Comparing the effects of rapid versus delayed tacrolimus initiation on graft function during the first three months after kidney transplantation. Study design: Randomized, open-label, phase three clinical trial. The method of study: a-The study population: Inclusion criteria; all patients  $\geq 14$  years who will receive first kidney transplantation and they're immunosuppressive regimen contains thymoglobulin induction along with mycophenolate, tacrolimus and prednisolone as maintenance regimen. Exclusion criteria: Patients who have multiple organ transplantation. Sample size: 25 patients in each group. b-Intervention or interventions studied: one group of patients will be administered tacrolimus from a few hours before transplantation at a dose of 0.08 to 0.1 mg / kg / day in two divided doses and continue from the first day after transplantation (with the target level of 8-10 ng / ml) . The second group will start tacrolimus with the same dose from the third day after transplantation. c- Intervention time: First three days after kidney transplantation. d-The primary outcome or consequences studied: -Dialy evaluation of serum creatinine and urine output and required dialysis during hospitalization. - Comparing the incidence and duration of DGF and ATN during hospitalization -Comparing the incidence of acute rejection within the first 3 months after transplantation - Compare the serum creatinine concentrations at the discharge time -Compare rates of graft survival within first 3 months after transplantation

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201604253043N11**  
Registration date: **2016-05-21, 1395/03/01**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2016-05-21, 1395/03/01

##### Registrant information

###### Name

Simin Dashti-Khavidaki

###### Name of organization / entity

Tehran University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 6695 4709

###### Email address

dashtis@sina.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Governmental (Tehran University of Medical Sciences)

##### Expected recruitment start date

2016-05-21, 1395/03/01

##### Expected recruitment end date

2017-09-21, 1396/06/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparing de novo versus delayed tacrolimus administration on allograft function in kidney transplant recipients: a randomized, open-label, clinical trial

## Public title

Comparing the starting time of tacrolimus administration in management of kidney transplant recipients

## Purpose

Prevention

## Inclusion/Exclusion criteria

Inclusion criteria: All patients who underwent the first of Deceased donor or Living donor kidney transplantation in Imam Khomeini Hospital Complex, Tehran, Iran ; Age is  $\geq$  14 y ; Patients who receive thymoglobulin induction ; Patients who receive Mycophenolate and Prednisone plus Tacrolimus as immunosuppressive regimen. Exclusion criteria: Patients with unstable cardiac, hepatic, pulmonary functions after kidney transplantation ; Patients who have multiple organ transplantation ; Patients with known malignancy.

## Age

From **14 years** old to **75 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

No information

## Sample size

Target sample size: **50**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Tehran University of Medical Sciences

##### Street address

Tehran University of Medical Sciences, 16 Azar St., Enghelab St, Tehran, Iran.

##### City

Tehran

##### Postal code

#### Approval date

2016-05-09, 1395/02/20

#### Ethics committee reference number

IR.TUMS.REC.1395.2575

## Health conditions studied

### 1

#### Description of health condition studied

Kidney transplant

#### ICD-10 code

Z94.0

#### ICD-10 code description

Kidney transplant status

## Primary outcomes

### 1

#### Description

Recipient's serum creatinine

#### Timepoint

Before the transplantation, every 6 hours on the first day of transplant, then daily during hospitalization, then weekly until the end of the first month after transplant, then monthly until the end of the third month after transplant

#### Method of measurement

Blood samples in laboratories in milligrams / deciliter

### 2

#### Description

Recipient's urine output

#### Timepoint

Before transplantation and daily during hospitalization

#### Method of measurement

Graduated container in ml/day

### 3

#### Description

Incidence of DGF

#### Timepoint

During first week after transplantation

#### Method of measurement

Need for dialysis

## Secondary outcomes

### 1

#### Description

Graft survival

#### Timepoint

First three months after transplantation

#### Method of measurement

Number of functioning kidney

### 2

#### Description

The incidence of acute rejection

#### Timepoint

During the first three months after transplantation

#### Method of measurement

Based on function of transplanted kidney

## Intervention groups

### 1

#### Description

Intervention 1: Tacrolimus will be started from a few hours before transplantation at a dose of 0.08 to 0.1 mg / kg / day in two divided doses ( The target level of 8-10 ng / ml). Serum creatinine and urine output will be assessed daily during hospitalization. Serum creatinine will be assessed monthly after hospital discharge up to month 3 after kidney transplantation. Tacrolimus whole blood concentrations will be checked twice weekly during hospitalizations and monthly thereafter up to month 3 after transplantation.

#### Category

Prevention

### 2

#### Description

Intervention 2: Tacrolimus will be started from the third day after kidney transplantation at a dose of 0.08 to 0.1 mg / kg / day in two divided doses (The target level of 8-10 ng / ml). Serum creatinine and urine output will be assessed daily during hospitalization. Serum creatinine will be assessed monthly after hospital discharge up to month 3 after kidney transplantation. Tacrolimus whole blood concentrations will be checked twice weekly during hospitalizations and monthly thereafter up to month 3 after transplantation.

#### Category

Prevention

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Kidney transplant ward, Imam Khomeini Hospital Complex

##### Full name of responsible person

Dr Maryam Ghadimi

##### Street address

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Tehran University of Medical Sciences

##### Full name of responsible person

Dr Masoud Younesian

##### Street address

16 Azar St., Faculty of Pharmacy, Tehran University of Medical Sciences

##### City

Tehran

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Tehran University of Medical Sciences

##### Proportion provided by this source

100

##### Public or private sector

empty

##### Domestic or foreign origin

empty

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

empty

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Department of Clinical Pharmacy, Tehran University of Medical Sciences

##### Full name of responsible person

Dr Maryam Ghadimi

##### Position

Resident of Clinical Pharmacy

##### Other areas of specialty/work

##### Street address

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16Azar St.

##### City

Tehran

##### Postal code

##### Phone

+98 21 6695 4709

##### Fax

##### Email

ghadimimaryam4449@yahoo.com

##### Web page address

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Tehran University of Medical Sciences

##### Full name of responsible person

Dr. Simin Dashti-Khavidaki

##### Position

Professor of Clinical Pharmacy

##### Other areas of specialty/work

##### Street address

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16Azar St.

##### City

Teharn  
**Postal code**  
**Phone**  
+98 21 6695 4709  
**Fax**  
**Email**  
dashtis@sina.tums.ac.ir  
**Web page address**

Tehran  
**Postal code**  
**Phone**  
+98 21 6695 4709  
**Fax**  
**Email**  
ghadimimaryam4449@yahoo.com  
**Web page address**

## Person responsible for updating data

### Contact

#### **Name of organization / entity**

Department of Clinical Pharmacy, Tehran University  
of Medical Sciences

#### **Full name of responsible person**

Dr Maryam Ghadimi

#### **Position**

Resident of Clinical Pharmacy

#### **Other areas of specialty/work**

#### **Street address**

Department of Clinical Pharmacy, Faculty of  
Pharmacy, Tehran University of Medical Sciences, 16  
Azar St.

#### **City**

## Sharing plan

### **Deidentified Individual Participant Data Set (IPD)**

*empty*

### **Study Protocol**

*empty*

### **Statistical Analysis Plan**

*empty*

### **Informed Consent Form**

*empty*

### **Clinical Study Report**

*empty*

### **Analytic Code**

*empty*

### **Data Dictionary**

*empty*